- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07385443
Le registre national espagnol pour la dystrophie myotonique de type 1 (DM1-Hub)
Création d'un Nœud Intégral Pour la Dystrophie Myotonique de Type 1 en Espagne : Registre clinique, Cartes génomiques, épigénomiques et protéomiques (DM1-Hub)
Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.
The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The DM1-Hub Patient Registry (https://www.dm1spain.com/) aims to recruit individuals living in Spain with a confirmed genetic diagnosis of myotonic dystrophy type 1 (DM1). Participants may be referred by healthcare professionals or patient organizations. They may also learn about the registry through outreach activities, informational materials, collaborations with national and local patient associations, DM1-Hub events, or through their own online searches.
After completing the informed consent process with their neurologist, participants are connected with the DM1-Hub patient support staff assigned to their hospital. An appointment is scheduled, and all the data collected is entered into the REDCap database.
The objective of this study is to establish a Natural History Patient Registry for individuals with DM1 in Spain. Participants will be invited to take part in follow-up assessments to support the characterization of disease progression over time. A parallel control group will also be recruited to facilitate biomarker discovery and improve understanding of factors associated with disease prognosis.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Gisela Nogales Gadea, Ph.D.
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: gnogales@igtp.cat
Sauvegarde des contacts de l'étude
- Nom: Alvaro S Larran Mottino, Ph.D.
- E-mail: alarran@igtp.cat
Lieux d'étude
-
-
Andalusia
-
Multiple Locations, Andalusia, Espagne
- Recrutement
- Hospitals within the DM1 network
-
Contact:
- Dr. Macarena Cabrera
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Chercheur principal:
- Dr. Macarena Cabrera
-
-
Basque Country
-
Multiple Locations, Basque Country, Espagne
- Recrutement
- Hospitals within the DM1 network
-
Contact:
- Dr. Andone Sistiaga
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Chercheur principal:
- Dr. Andone Sistiaga
-
-
Canary Islands
-
Multiple Locations, Canary Islands, Espagne
- Recrutement
- Hospitals within the DM1 network
-
Contact:
- Dr. Jorge Alonso
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Chercheur principal:
- Dr. Jorge Alonso
-
-
Cantabria
-
Multiple Locations, Cantabria, Espagne
- Recrutement
- Hospitals within the DM1 network
-
Contact:
- Dr. Ana Lara Pelayo
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Chercheur principal:
- Dr. Ana Lara Pelayo
-
-
Castilla-La Macha
-
Multiple Locations, Castilla-La Macha, Espagne
- Recrutement
- Hospitals within the DM1 network
-
Contact:
- Dr. Jorge García
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Chercheur principal:
- Dr. Jorge García
-
-
Catalonia
-
Multiple Locations, Catalonia, Espagne
- Recrutement
- Hospitals within the DM1 network
-
Contact:
- Dr. Sebastián Figueroa
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Chercheur principal:
- Dr. Sebastián Figueroa
-
-
Madrid
-
Multiple Locations, Madrid, Espagne
- Recrutement
- Hospitals within the DM1 network
-
Contact:
- Dr. Gerardo Gutiérrez
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Chercheur principal:
- Dr. Gerardo Gutiérrez
-
-
Valencia
-
Multiple Locations, Valencia, Espagne
- Recrutement
- Hospitals within the DM1 network
-
Contact:
- Dr. Nuria Muelas
- Numéro de téléphone: (+34) 93 554 3050
- E-mail: dm1-hub@igtp.cat
-
Chercheur principal:
- Dr. Nuria Muelas
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Participants with Myotonic Dystrophy Type 1 (DM1) will volunteer to participate in this study. The study will be advertised through physician recommendations, outreach and educational activities directed at neuromuscular professionals, the registry website, national and local patient associations, and through patient-focused events, conferences, and scientific meetings across Spain.
La description
Inclusion Criteria:
- Confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1) through genetic testing.
Exclusion Criteria:
- There are no exclusion criteria for the registry
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Myotonic Dystrophy Type 1 (DM1)
The group included Individuals with a confirmed genetic diagnosis of Myotonic Dystrophy Type 1 (DM1) |
Patient Registry |
|
Control
The group included control subjects as individuals without a genetic diagnosis of Myotonic Dystrophy Type 1 (DM1). |
Patient Registry |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Genomic Caracterization
Délai: 1 year, year 1
|
Long-read genomic sequencing analyses encompassing CTG expansion characterization and whole-genome genetic and epigenetic profiling. |
1 year, year 1
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proteomic Characterization
Délai: 1 year, year 1
|
Biomarker evaluation |
1 year, year 1
|
|
WAIS IV neuropsychological tests
Délai: 2 years, year 1
|
IQ, memory, attention, language |
2 years, year 1
|
|
vHOT
Délai: 1 year, year 1
|
Video Hand Opening Time, clinical measure for Myotonic Dystrophy (DM1) tracking hand reopening speed |
1 year, year 1
|
|
Muscular Impairment Rating Scale (MIRS)
Délai: 1 year, year 1
|
The Muscular Impairment Rating Scale is a 5-point ordinal clinical scale used to evaluate the severity of muscular impairment in patients with myotonic dystrophy. Scores range from 1 (minimal or no impairment) to 5 (severe muscle impairment). Higher scores indicate worse functional impairment. |
1 year, year 1
|
|
Hand Grip Strength
Délai: 1 year, year 1
|
Hand grip strength is assessed as a measure of upper limb muscle strength using a hand-held dynamometer. Grip strength is measured separately in the dominant and non-dominant hand, and recorded in kilograms (kg). For each hand, three consecutive attempts are performed, alternating between hands to minimize fatigue. The maximum value (best of three attempts) for each hand is recorded and used for analysis. Higher values indicate better muscle strength and functional outcome, while lower values reflect greater muscular impairment. |
1 year, year 1
|
|
6MWT
Délai: 1 year, year 1
|
Six-Minute Walk Test |
1 year, year 1
|
|
10MWRT
Délai: 1 year, year 1
|
10-meter Walk/Run Test |
1 year, year 1
|
|
30CST
Délai: 1 year, year 1
|
30-Second Chair Stand Test |
1 year, year 1
|
|
FVC
Délai: 1 year, year 1
|
Forced Vital Capacity (L) |
1 year, year 1
|
|
Electrocardiogram (ECG)
Délai: 1 year, year 1
|
The following ECG-derived parameters and abnormalities are recorded:
All measurements are extracted from the ECG tracing according to standard clinical practice. Higher PR or QRS durations and the presence of conduction abnormalities or arrhythmias indicate greater cardiac involvement, while normal values and absence of abnormalities indicate preserved cardiac electrical function. |
1 year, year 1
|
|
BMI
Délai: 1 year, year 1
|
Body Mass Index |
1 year, year 1
|
|
OBGYN events
Délai: 1 year, year 1
|
Collection of gynecological clinical history and relevant reproductive health events for participants who opt to provide this information. |
1 year, year 1
|
|
GI symptomatology
Délai: 1 year, year 1
|
Collection of participant-reported gastrointestinal symptoms and related clinical information. |
1 year, year 1
|
|
MBS (Myotonia Behaviour Scale)
Délai: 1 year, year 1
|
Myotonia severity is assessed using the Myotonia Behaviour Scale (MBS), a clinician-reported ordinal scale that evaluates the functional impact of myotonia-related muscle stiffness on daily activities. The scale ranges from 0 to 5, with higher scores indicating greater severity and functional interference due to myotonia: 0: No muscle stiffness
Lower scores reflect minimal or absent myotonia, while higher scores reflect greater functional impairment due to myotonia. |
1 year, year 1
|
|
Modified Rankin Scale (mRS)
Délai: 1 year, year 1
|
Global disability is assessed using the Modified Rankin Scale (mRS), a widely used ordinal scale measuring the degree of disability or dependence in daily activities. The scale ranges from 0 to 6, with higher scores indicating greater disability or death: 0: No symptoms
|
1 year, year 1
|
|
Patient-Reported Outcome: Quality of life
Délai: 1 year, year 1
|
INQoL (Individualized Neuromuscular Quality of Life Questionnaire) |
1 year, year 1
|
|
Patient-Reported Outcome: Fatigue
Délai: 1 year, year 1
|
FSS (Fatigue Severity Scale ) |
1 year, year 1
|
|
Patient-Reported Outcome: Dietary Habits
Délai: 1 year, year 1
|
MEDAS-14 (Mediterranean Diet Adherence Screener) |
1 year, year 1
|
|
Patient-Reported Outcome: Sleepiness
Délai: 1 year, year 1
|
DSS (Daytime Sleepiness Scale) |
1 year, year 1
|
|
Patient-Reported Outcome: Apathy
Délai: 1 year, year 1
|
AES (Apathy Evaluation Scale) |
1 year, year 1
|
|
Patient-Reported Outcome: Physical Activity
Délai: 1 year, year 1
|
IPAQ (International Physical Activity Questionnaire) |
1 year, year 1
|
|
Patient-Reported Outcome: Mental Health
Délai: 1 year, year 1
|
MHI-5 (Mental Health Inventory) |
1 year, year 1
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Gisela Nogales Gadea, Ph.D., Germans Trias i Pujol Research Institute
- Chercheur principal: Arturo Lopez Castel, Ph.D., INCLIVA Instituto de Investigación Sanitaria
- Chercheur principal: Virginia Arechavala-Gomeza, Ph.D., IIS Biobizkaia
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies musculo-squelettiques
- Maladies du système nerveux
- Maladies musculaires
- Maladies neuromusculaires
- Maladies génétiques, innées
- Maladies neurodégénératives
- Troubles hérédodégénératifs, système nerveux
- Troubles musculaires atrophiques
- Dystrophies musculaires
- Troubles myotoniques
- Maladies et anomalies congénitales, héréditaires et néonatales
- Dystrophie myotonique
Autres numéros d'identification d'étude
- PMPER24/00007
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .